MeNZB
Meningococcal vaccine in New Zealand / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about MeNZB?
Summarize this article for a 10 year old
MeNZB was a vaccine against a specific strain of group B meningococcus,[1] used to control an epidemic of meningococcal disease in New Zealand. Most people are able to carry the meningococcus bacteria safely with no ill effects. However, meningococcal disease can cause meningitis and sepsis, resulting in brain damage, failure of various organs, severe skin and soft-tissue damage, and death.
This article needs additional citations for verification. (February 2009) |
Vaccine description | |
---|---|
Target | group B meningococcus strain |
Vaccine type | Subunit |
Clinical data | |
Routes of administration | Injected |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
NY (what is this?) (verify) |
Immunisation with MeNZB requires three doses, administered approximately six weeks apart (except in newborns, who have them in conjunction with their 6-week, 3-month and 5-month injections). People who have been fully immunised may still carry the meningococcus bacteria and may still contract meningococcal disease.